Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Mechanism of Sublingual Immunotherapy with Dust Mite Allergen for Perennial Allergic Rhinitis
NCT05570383Phase 3Unknown
- Sponsor
- People's Hospital of Anshun City
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dermatophagoides farinae allergen extract in allergic rhinitis (AR) (2 arms), sponsored by People's Hospital of Anshun City. Primary endpoints: Total Nasal Symptom Score at 3 months, Visual Analogue Scale at 3 months and 3 more. Status: unknown.
02
Drugs
dermatophagoides farinae allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05570383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570383.